<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02900716</url>
  </required_header>
  <id_info>
    <org_study_id>D15-11094</org_study_id>
    <nct_id>NCT02900716</nct_id>
  </id_info>
  <brief_title>Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas</brief_title>
  <official_title>A Phase Ia/Ib Study of a Novel BTK Inhibitor, DTRMWXHS-12, and Combination Products, DTRM-505 and DTRM-555, in Patients With Chronic Lymphocytic Leukemia or Other B-cell Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang DTRM Biopharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang DTRM Biopharma</source>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, antitumor activity and preliminary pharmacokinetics of&#xD;
      an investigational drug product, DTRMWXHS-12, in patients with chronic lymphocytic leukemia&#xD;
      or other B-cell lymphomas. DTRMWXHS-12 will be evaluated as a single agent, and in&#xD;
      combination.&#xD;
&#xD;
      This study will be conducted in two parts: phase Ia and Ib. Both parts will explore&#xD;
      escalating doses of DTRMWXHS-12. The phase Ia study will evaluate DTRMWXHS-12 monotherapy.&#xD;
      The phase Ib study will evaluate DTRMWXHS-12 combinations.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Actual">November 23, 2020</completion_date>
  <primary_completion_date type="Actual">November 23, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>Starting from date of first dose up to 30 days after last dose</time_frame>
    <description>Safety and tolerability</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration over time</measure>
    <time_frame>Days 1-28 (first treatment cycle)</time_frame>
    <description>Pharmacokinetics</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>B-Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Phase Ia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DTRMWXHS-12: oral capsules, daily x 21 days every 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase Ib, DTRM-505</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DTRMWXHS-12 oral capsules and everolimus oral tablets: daily x 21 days every 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase Ib, DTRM-555</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DTRMWXHS-12 and pomalidomide oral capsules, everolimus oral tablets:&#xD;
daily x 21 days every 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DTRMWXHS-12</intervention_name>
    <description>DTRMWXHS-12</description>
    <arm_group_label>Phase Ia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DTRM-505</intervention_name>
    <description>DTRMWXHS-12 and everolimus</description>
    <arm_group_label>Phase Ib, DTRM-505</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DTRM-555</intervention_name>
    <description>DTRMWXHS-12 and everolimus and pomalidomide</description>
    <arm_group_label>Phase Ib, DTRM-555</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a diagnosis of chronic lymphocytic leukemia (CLL) or other B-cell&#xD;
             neoplasms including small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL),&#xD;
             marginal zone lymphoma (MZL) and follicular B-cell non-Hodgkin's lymphoma (FL) who&#xD;
             have no available approved therapies.&#xD;
&#xD;
          -  Age &gt; 18 years.&#xD;
&#xD;
          -  Life expectancy greater than 12 weeks.&#xD;
&#xD;
          -  Patients must have an ECOG (Eastern Cooperative Oncology Group) performance status 0&#xD;
             or 1.&#xD;
&#xD;
          -  Patients must provide written informed consent.&#xD;
&#xD;
          -  Ability to swallow and retain capsules.&#xD;
&#xD;
          -  Absence of uncontrolled intercurrent illnesses, including uncontrolled infections,&#xD;
             cardiac conditions, or other organ dysfunctions.&#xD;
&#xD;
          -  Women of child-bearing potential must have a negative serum or urine pregnancy test.&#xD;
&#xD;
          -  Women of child-bearing potential must agree to use 2 reliable methods of contraception&#xD;
             beginning 4 weeks prior to the initiation of treatment, during therapy, and for at&#xD;
             least 4 weeks after the last drug administration.&#xD;
&#xD;
          -  Men must agree to use a latex or synthetic condom during sexual contact with a&#xD;
             pregnant female or a female who can become pregnant, for the duration of the study and&#xD;
             for at least 4 weeks after the last drug administration, even if they have undergone a&#xD;
             successful vasectomy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Received previous chemotherapy, immunotherapy, radiotherapy or any other&#xD;
             investigational therapy within 21 days or 5 half-lives for targeted therapies prior to&#xD;
             this study entry.&#xD;
&#xD;
          -  Patients with active infections requiring intravenous (IV) antibiotic/antiviral&#xD;
             therapy are not eligible for entry onto the study until resolution of the infection;&#xD;
             patients on prophylactic antibiotics, antifungals or antivirals are acceptable&#xD;
&#xD;
          -  Pregnant or lactating individuals.&#xD;
&#xD;
          -  Impaired hepatic or renal function as demonstrated by any of the following laboratory&#xD;
             values:&#xD;
&#xD;
               1. AST or ALT &gt; 2.5 x ULN&#xD;
&#xD;
               2. Total bilirubin &gt; 1.5 x ULN (Patients with a history of Gilbert's syndrome may&#xD;
                  participate if total bilirubin is less than or equal to 1.5 x ULN and the AST/ALT&#xD;
                  and alkaline phosphatase meet the protocol-specified levels for eligibility)&#xD;
&#xD;
               3. Alkaline phosphatase &gt; 2.5 x ULN&#xD;
&#xD;
               4. Glomerular filtration rate (GFR) &lt; 50 mL/min, as assessed using the standard&#xD;
                  methodology at the investigating center (i.e. Cockroft-Gault), or serum&#xD;
                  creatinine &gt; 1.5 x ULN&#xD;
&#xD;
          -  INR &gt; 1.5 or other evidence of impaired hepatic synthesis function.&#xD;
&#xD;
          -  Persisting (&gt; 8 weeks) severe pancytopenia due to hematologic disorder or due to&#xD;
             previous therapy rather than disease (ANC &lt; 0.5 x 109/L or platelets &lt; 30 x 109/L) -&#xD;
             to be confirmed via bone marrow biopsy, as part of normal clinical care, prior to&#xD;
             signing of consent.&#xD;
&#xD;
          -  Previous allogeneic bone marrow transplant are restricted, unless there is no evidence&#xD;
             of acute or chronic graft versus host disease.&#xD;
&#xD;
          -  CNS involvement with malignancy.&#xD;
&#xD;
          -  Current malignancies of another type, with the exception of adequately treated in situ&#xD;
             cervical cancer and basal cell skin cancer, squamous cell carcinoma of the skin or&#xD;
             other malignancies with no evidence of disease for 2 years or more.&#xD;
&#xD;
          -  Known history of HIV, HBV or HCV infection.&#xD;
&#xD;
          -  Documented or known bleeding disorder.&#xD;
&#xD;
          -  Requirement for anticoagulation treatment that increases INR or aPTT above the normal&#xD;
             range (low molecular weight heparin and heparin line flush allowed).&#xD;
&#xD;
          -  Patient is receiving any azole.&#xD;
&#xD;
          -  Patients with a significant cardiovascular disease or condition, including:&#xD;
&#xD;
               -  Myocardial infarction within 6 months of study entry&#xD;
&#xD;
               -  NYHA Class III or IV heart failure, or reduced LVEF &lt;50%&#xD;
&#xD;
               -  Uncontrolled dysrhythmias or poorly controlled angina.&#xD;
&#xD;
               -  History of serious ventricular arrhythmia (VT or VF, ≥ 3 beats in a row) and/or&#xD;
                  risk factors (e.g., heart failure, hypokalemia, family history of Long QT&#xD;
                  Syndrome)&#xD;
&#xD;
               -  Baseline prolongation of QT/QTc interval (repeated demonstration of QTc ≥ 450&#xD;
                  msec for men and 470 msec for women, or LVEF ≤ 40% by MUGA or ECHO).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei He, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Zhejiang DTRM Biopharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Abramson Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>August 18, 2016</study_first_submitted>
  <study_first_submitted_qc>September 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2016</study_first_posted>
  <last_update_submitted>November 24, 2020</last_update_submitted>
  <last_update_submitted_qc>November 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

